Teriparatide

Teriparatide is the first 34 residues of human parathyroid hormone, which is the whole of the receptor-binding and activating region. It binds the PTH1 receptor on osteoblasts and osteocytes, driving cyclic AMP and protein kinase A signalling. The critical variable is exposure time: a brief daily pulse increases osteoblast number and survival and suppresses sclerostin, producing net bone formation, whereas the continuous elevation seen in primary hyperparathyroidism drives RANKL-mediated osteoclast activity and net bone loss. This is why it must be injected once daily rather than delivered by any sustained-release system. Bone mineral density gains at the lumbar spine are large, typically 8 to 13 percent over 18 to 24 months, with vertebral fracture risk reduced by roughly two thirds.

Targets: PTH1 receptor, Osteoblast proliferation and survival, Sclerostin suppression, Renal 1-alpha-hydroxylase

• · Fixed 20 mcg dose from a multi-dose pen delivering 28 daily doses. Not titrated.

Work out your exact syringe units →

• commonOrthostatic hypotension and dizziness— Concentrated in the first few doses; inject seated.
• commonNausea
• commonLeg cramps
• commonTransient hypercalcaemia— Peaks 4 to 6 hours after the dose and usually normalises by 16 to 24 hours.
• commonInjection-site reaction
• uncommonHypercalciuria and kidney stones— Relevant in patients with a stone history.

• Pre-existing hypercalcaemia or primary hyperparathyroidism
• Paget's disease of bone or unexplained elevated alkaline phosphatase
• Prior external beam or implant radiation therapy involving the skeleton
• Bone metastases or skeletal malignancy
• Severe renal impairment
• Open epiphyses in young patients

• redundantabaloparatide — Both are anabolic PTH-pathway agents; you use one or the other, and the total anabolic exposure counts toward the same lifetime consideration.
• conflictcalcitonin-salmon — Directly opposing effects on bone turnover; there is no rationale for combining them.

• · Serum calcium before starting and at about 1 month
• · 25-hydroxyvitamin D and adequate calcium intake
• · DXA at 12 to 24 months
• · P1NP if you want early confirmation of anabolic response
• · Urinary calcium in patients with a stone history

Prescription drug in the US and EU. Biosimilar and generic teriparatide pens are now available and much cheaper than the originator.

• Forteo FDA prescribing information (label)
• Neer et al. 2001 NEJM, Fracture Prevention Trial of teriparatide in postmenopausal osteoporosis (trial)
• Endocrine Society guideline on pharmacological management of osteoporosis in postmenopausal women (guideline)

The entire drug is an argument about exposure time rather than about a molecule. PTH1R is a class B GPCR that adopts two functionally distinct high-affinity conformations. R0 is G-protein-independent and produces prolonged cyclic AMP signalling from internalised receptor-ligand complexes; RG is the G-protein-coupled conformation producing a short, sharp signal that terminates when the ligand washes off. Teriparatide's 1-hour subcutaneous half-life and 3-hour disappearance mean each daily injection delivers a pulse, not a plateau. That pulse activates PKA and PKC in osteoblasts and osteocytes, drives Runx2 and CREB-dependent transcription, increases osteoblast recruitment from lining cells and precursors, and critically suppresses osteoblast apoptosis, expanding the working osteoblast population. It also suppresses sclerostin transcription in osteocytes, releasing the brake on Wnt/beta-catenin signalling, which is a large part of why bone formation markers move first. The consequence is an anabolic window in the first 6 to 12 months where formation markers rise steeply and resorption markers lag, and bone is added. Continuous exposure, as in primary hyperparathyroidism or a hypothetical depot formulation, instead sustains RANKL expression relative to osteoprotegerin, recruits osteoclasts and produces net cortical bone loss. Same receptor, same ligand, opposite outcome, decided purely by kinetics. The anabolic window also explains why gains are lost within a year of stopping unless an antiresorptive follows: you have built new bone into a high-turnover skeleton and nothing is defending it.

The commonest real-world failures are logistical. The pen must stay refrigerated at all times, including throughout its 28-day in-use period, which makes travel genuinely awkward and produces a lot of accidentally discarded pens. It cannot be frozen, and a pen that has frozen must go in the bin. Second, the timing of the calcium check: a sample drawn 4 to 6 hours after the injection catches the physiological peak and generates a false hypercalcaemia panic, so it must be drawn pre-dose or at least 16 hours out. Third, orthostatic hypotension in the first few doses puts people on the floor, and the fix is simply to inject sitting or lying down for the first week. Fourth, and most consequentially, stopping without a follow-on antiresorptive: bone mineral density and fracture protection decay within a year and the patient has spent 18 to 24 months and a great deal of money for a temporary result. Fifth, using it in someone with an unexplained raised alkaline phosphatase or prior skeletal radiation, both of which are contraindications for a reason.

1. 20 mcgWeeks 1-104 — 20 mcg subcutaneously once daily from a pen delivering 28 doses. There is no titration ladder: the dose is fixed and the only variables are duration and what follows it. Take the first several doses sitting or lying down because orthostatic hypotension clusters in the first few hours of the first few injections.

• PTH1 receptor on osteoblasts and osteocytes — High; teriparatide is the full agonist that defines the receptor. Numeric Kd not resolved this session.

  Gs-cyclic AMP-PKA and Gq-PKC signalling. Increases osteoblast number and lifespan, suppresses osteoblast apoptosis, and transcriptionally suppresses sclerostin, releasing Wnt signalling. Intermittent exposure favours formation; continuous exposure favours RANKL-driven resorption.

• PTH1 receptor in renal proximal and distal tubule — High

  Increases distal tubular calcium reabsorption, reduces phosphate reabsorption, and stimulates 1-alpha-hydroxylase to make 1,25-dihydroxyvitamin D, raising intestinal calcium absorption. This is the source of the transient hypercalcaemia and the hypercalciuria.

• Sclerostin (SOST) expression

  Transcriptionally suppressed within hours of each dose, which is the fastest-moving molecular event in the anabolic response.

• Fracture Prevention Trial Phase 3, randomised, double-blind, placebo-controlled · 2001

  New vertebral fractures in postmenopausal women with prior vertebral fracture. Teriparatide 20 mcg daily reduced new vertebral fractures by roughly two thirds and non-vertebral fragility fractures by around half versus placebo. The trial was stopped early when rat osteosarcoma data emerged, which is why median exposure was about 18 months rather than the planned 3 years.

P1NP rises within the first month and often within 2 weeks, which makes it the fastest available confirmation of response. Bone mineral density at the lumbar spine becomes measurable at about 6 months and continues to climb through 18 to 24 months, ending 8 to 13 percent above baseline in most responders. Hip and cortical sites move much more slowly and can dip transiently in the first 6 months as remodelling space opens. Fracture risk reduction accrues over roughly 18 months. The anabolic window, meaning the period when formation exceeds resorption, is widest in the first 6 to 12 months and narrows thereafter, which is the pharmacological reason treatment beyond 24 months adds little.

The sequencing question matters more than the stacking question. Anabolic first, antiresorptive second, is the correct order: teriparatide after a bisphosphonate gives a blunted early bone mineral density response, particularly at the hip, because the skeleton is locked down and the remodelling space is closed. Teriparatide before a bisphosphonate or denosumab preserves and consolidates the gain. Following teriparatide with nothing throws away most of what you built within a year, and that is the single most common expensive mistake with this drug. Concurrent denosumab plus teriparatide is the one combination with genuine randomised evidence of additive bone mineral density gain beyond either alone, and it is used in very high risk patients, though it is off-label and expensive. Do not combine with a bisphosphonate concurrently, and do not combine with abaloparatide or calcitonin. Adequate calcium, around 1000 mg daily from all sources, and vitamin D repletion are prerequisites rather than adjuncts. Thiazides are worth remembering as calcium-retaining and can push a borderline patient hypercalcaemic.

Against abaloparatide: comparable spine bone mineral density gains, abaloparatide gets to non-vertebral fracture reduction faster and produces less hypercalcaemia, and its pen does not need refrigeration once in use. Teriparatide has 20 years more real-world safety data and now has cheap biosimilars, which is a real advantage. Against romosozumab: romosozumab is a sclerostin antibody with both anabolic and antiresorptive action, gives larger bone mineral density gains over 12 months and beat alendronate on fracture outcomes, but carries a cardiovascular boxed warning teriparatide does not. Against bisphosphonates and denosumab: those slow loss, teriparatide builds. In a patient with severe established osteoporosis and recent fractures, starting with an antiresorptive is arguably the wrong move, because it makes the subsequent anabolic response worse. The osteosarcoma boxed warning is gone, having failed to appear in more than 15 years of human surveillance, and treating it as a live concern in 2026 is out of date.

$400–$3500/month. Unverified estimate. Generic and biosimilar teriparatide pens in the US are dramatically cheaper than branded Forteo, and the gap is large enough that it dominates the prescribing decision. Not sourced in this session.

• ?The one-letter and three-letter sequences given are the standard published human PTH(1-34) sequence and I am confident in them, but the Forteo label renders the sequence as a figure rather than text and I could not confirm it character by character this session, so verified is false.
• ?Volume of distribution is converted from the label's 0.12 L/kg using a 70 kg reference weight; the label does not give a litre value.
• ?Plasma protein binding is not stated anywhere in the label.
• ?The Fracture Prevention Trial enrolled roughly 1,600 women with a median 19 months of treatment, but I did not confirm those figures, so both are null.
• ?Cost figures are unverified estimates.

• Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis Neer RM, et al., New England Journal of Medicine, 2001 · PMID 11346808

  The Fracture Prevention Trial. Still the reference dataset for anabolic osteoporosis therapy.

• FORTEO (teriparatide) injection - FDA prescribing information Eli Lilly and Company, DailyMed

  Source of the 95 percent bioavailability, 30 minute tmax, 0.12 L/kg volume of distribution, 62 L/h female and 94 L/h male clearance, and the statement that no formal metabolism studies exist.